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Background: Use of contraception lowers a woman's risk of experiencing an ectopic pregnancy. In the case of method failure, however,
progestin-only contraceptives may be more likely to result in ectopic pregnancies than some other methods such as combined hormonal and
barrier contraceptives.
Objective: To describe ectopic pregnancy risk associated with use of implants and progestin-only injectable contraceptives through a
systematic review of published studies.
Data Sources: We searched electronic databases for articles in any language published through May 2015 describing studies of progestin-
only injectables and implants. We also searched bibliographies and review articles for additional studies.
Study Selection and Extraction: Studies that reported any pregnancies were included in the review. Independent data extraction was
performed by two authors based on predefined data fields, and where possible, we calculated the proportion of pregnancies that were ectopic
and the ectopic pregnancy incidence rate per 1000 woman–years.
Results: Fifty-three studies of implants and 28 studies of injectables were identified; 79% reported pregnancy location. The proportion of ectopic
pregnancy ranged from 0 to 100% with an incidence of 0–2.9 per 1000 woman–years in studies of marketed levonorgestrel implants. Studies of
etonogestrel implants and the injectables, depot-medroxyprogesterone acetate and norethisterone enanthate, reported few ectopic pregnancies.
Conclusion: Progestin-only contraceptive implants and injectables protect against ectopic pregnancy by being highly effective in preventing
pregnancy overall; however, the absolute risk of ectopic pregnancy varies by type of progestin. Risk of ectopic pregnancy should not be a
deterrent for use or provision of these methods.
© 2015TheAuthors. Published byElsevier Inc. This is an open access article under theCCBY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Contraception; Ectopic pregnancy; Progestins; Implants; Injectables1. Introduction
1.1. Rationale
Ectopic pregnancies are an important cause of maternal
morbidity and mortality worldwide. In the United States and
other developed countries, an estimated 1–2% of all
pregnancies are ectopic [1–3], accounting for 3–5% of
pregnancy-related deaths [4,5]. In less developed regions,☆ Funding: This review was supported by the Bill & Melinda Gates
Foundation with additional support from the US Agency for International
Development under Award No. AID-GPO-A-00-10-00060.
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⁎ Corresponding author at: FHI 360, 359 Blackwell Street, Durham,
NC 27701. Tel.: +1-919-544-7040.
E-mail address: rcallahan@fhi360.org (R. Callahan).
http://dx.doi.org/10.1016/j.contraception.2015.08.016
0010-7824/© 2015 The Authors. Published by Elsevier Inc. This is an open access ardata on ectopic pregnancy are sparse; however, case fatality
is considerably higher [6–9].
Risk factors for ectopic pregnancy include, but are not
limited to, age, history of pelvic inflammatory disease (PID),
smoking, infertility, in vitro fertilization and prior ectopic
pregnancy [3,10,11]. An estimated half of ectopic pregnan-
cies appear to be caused by delay in transport of a fertilized
ovum to the uterus due to the damage of the fallopian tubes
caused by infection or surgery [12]. It has also been
hypothesized that low levels of progestin seen with some
progestin-only contraceptive methods, while failing to
inhibit ovulation, may impact tubal motility and increase
the risk of a pregnancy being ectopic [13]. The labels for the
levonorgestrel (LNG)-containing contraceptive implant
Jadelle® and the etonogestrel (ENG)-containing implant
Implanon® (and its successor, Nexplanon®) warn thatticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ectopic pregnancy because they lower the probability of
pregnancy, in the case of contraceptive failure, the implants
may be associated with an increase in the relative proportion
of pregnancies that are ectopic [14,15].
Women who experience method failure after female tubal
sterilization or while using hormonal or nonhormonal intrauter-
ine device (IUDs) or progestin-only pills (POPs) have been
reported to have a higher relative risk of ectopic pregnancy
than users of combined oral contraceptives (COCs) or condoms
[16–19]. A review of clinical data submitted to the Food and
Drug Administration for marketing approval of contraceptives
found that the proportion of pregnancies that were ectopic ranged
from 0 out of 27 among users of COCs, to 1 out of 21 among
POP users, to 1 out of 2 among users of the LNG IUD [20].
Several published reviews of ectopic pregnancy risk with the
use of sterilization, IUDs, POPs and emergency contraceptive
pills (ECPs) have been conducted [13,21–24]; however, no
thorough assessment of the association between progestin-only
implants or injectables and ectopic pregnancy has been
published. Understanding whether and how ectopic pregnancy
risk varies by these methods is important for both women and
providers, especially since common side-effects associated with
these methods, including irregular bleeding and lower abdom-
inal pain, can also be signs of ectopic pregnancy.
1.2. Objective
The objective of this review is to describe the risk of
ectopic pregnancy among users of progestin-only injectables
and contraceptive implants based on a comprehensive review
of published research.2. Methods
We conducted this systematic review in accordance with
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines [25].
2.1. Eligibility criteria
This review includes all published studies that presented
pregnancy data with use of any contraceptive implant (marketed
or not) and any progestin-only injectable. We included both
comparative analyses as well as single-arm observational
studies; however, studies that only presented pregnancy data
for subgroups of women (such as those on hepatic-enzyme
inducers or those participating in clinical trials of HIV
prevention drugs) were excluded.We also excluded case reports
and review articles, although relevant studies from review
articles were collected and evaluated for inclusion.
2.2. Search strategy and data extraction
We searched for studies of contraceptive implants or
injectables in any language that included pregnancy as an
outcome using the electronic databases MEDLINE (viaPubMed), POPLINE, LILACS andEMBASEpublished through
May 2015 (search terms listed in Appendix A). We also hand
searched reference lists and review articles for relevant studies.
Two authors (RC, IY) independently reviewed the search
results for studies potentially eligible for inclusion. Articles
considered potentially relevant and published in a language
other than English were translated by native speakers of the
particular language. Two authors (RC, IY) independently
read full-text articles to determine eligibility for inclusion,
that is, they presented data on pregnancy. For articles where
pregnancy site — intrauterine or ectopic — was not
reported, we contacted the authors via email to request this
information. After the list of eligible studies was established,
two authors (RC, IY) independently extracted data from the
studies using an extraction table developed for the purpose.
Extracted data included study design, length of follow-up,
contraceptive regimen(s), number of women–months and
women–years of exposure, number of pregnancies and
number of ectopic pregnancies. For articles in which the
number of women–years was not reported, it was calculated
by dividing the number of reported women–months by 12.
The proportion of pregnancies that were ectopic and ectopic
pregnancy incidence rate per 1000 woman–years was then
calculated for each regimen included in the study. After data
extraction was complete, the two authors compared results
and resolved any discrepancies.
2.3. Risk of bias in individual studies
While the aim of this review is to describe the risk of ectopic
pregnancy with use of progestin-only injectables and implants,
we do not present a summary estimate of risk for these methods
given the wide variation in research design, outcome measures
and study populations. We employed a comprehensive search
strategy designed to capture all relevant studies in order to
qualitatively describe risk. Given our broad inclusion criteria,
we did not attempt to assess data quality or the risk of bias for all
included studies. However, we do report study design and size
for each included study in Appendices B1 and B2.3. Results
Our search produced 884 potentially relevant articles, of
which 81met the eligibility criteria described above (Fig. 1).We
found 53 studies of progestin contraceptive implants [26–78]
and 28 studies of progestin-only injectables [79–106] reporting
any pregnancies. Most of the studies were prospective cohort
(n=41) or nonrandomized comparative (n=16) studies; howev-
er, 18 were randomized trials, five were chart reviews and one
was a review of regulatory agency surveillance data (Table 1).
3.1. Implants
The implant studies included seven different progestins and a
wide variety of regimens (Table 2). Some studies included
multiple progestins and multiple regimens. By far, the most
Papers identified through database 
searches published through April 2014
n=879
Papers identified through hand search of  
reference lists 
n=5 
Papers excluded through title/abstract review
n=743 
Full papers reviewed for eligibility
n=141 
Papersexcluded:
No pregnancy data, n=133 
Case reports, n=4
Papers included in review
n=81 
Fig. 1. Study selection.
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from studies of the six-rod 5-year implant system,Norplant®, (n=
28) containing 216mg of LNG. For 50 of the 53 implant studies,
location of pregnancy was either reported in the publication or
was obtained through correspondence with the study authors.
Forty-six studies reported woman–months or woman–years of
exposure allowing for calculation of ectopic pregnancy incidence.
3.1.1. Implants studied but not marketed
In general, studies of older nonmarketed implants reported
higher incidence of ectopic pregnancy (Table 2). For example,
the ectopic pregnancy incidence rate among women using a
single silastic capsule containing 47 mg of norgestrienone for 6
months was 51.8 per 1000 woman–years [57]. Women who
were implanted with five 30-mg capsules of megestrol acetateTable 1
Number of published studies of progestin-only implant and injectable
contraceptives reporting any pregnancies by study design.
Study design Implants
(N=53)
Injectables
(N=28)
Randomized controlled triala 8 10
Nonrandomized comparative cohort studyb 12 4
Prospective cohort studyc 30 11
Chart reviewd 2 3
Regulatory agency surveillance datae 1 –
a [34,42,47,53,65,71,75,77,79,81,86,87,95,96,100,102–104].
b [33,35,38,51,56–58,61,62,64,74,76,83,94,105,106].
c [26–32,36,37,39,40,44–46,48–50,52,54,55,59,60,63,66,67,69,70,
72,73,78,84,85,88–91,93,97–99,101].
d [41,43,80,82,92].
e [68].(MA) and used them for approximately 1 year had an ectopic
pregnancy incidence rate of 41.6 per 1000 woman–years [61].
The high pregnancy and ectopic pregnancy rates observed with
some of these early implants were important reasons why these
products never reached the market.
Among five studies of Norplant II, the predecessor to the
two-rod LNG-releasing implant Jadelle, that included site of
implantation, one reported an ectopic pregnancy at 15 months of
use in awomanwith a history of ectopic pregnancy [42] resulting
in an ectopic pregnancy rate of 2.6 per 1000 woman–years.
3.1.2. Marketed implants
Twenty-eight studies of Norplant are included in the review,
25 of which reported site of implantation. Among those 25, 14
(56%) reported no ectopic pregnancies. The ectopic pregnancy
incidence rate among the other 11 ranged from0.1 to 2.9 per 1000
woman–years, and the proportion of pregnancies that were
ectopic ranged from 3.1% to 100% (Table 2). The highest ectopic
incidence rate was reported in a study of 208 Norplant users (345
woman–years) in New York City [37]. In that study, an
intrauterine pregnancy at month 14 and an ectopic pregnancy at
month 24 occurred in women weighing more than 175 lb. Only
one other early study ofNorplant reported an ectopic incidence of
more than 2.0 [45]. In that study, only two pregnancies occurred;
however, both were ectopic. The remaining nine studies reported
rates under 1.0 ectopic pregnancies per 1000 W-Y.
Though fewer in number, studies of other marketed
LNG-containing implants including Jadelle (150 mg), Sino-
implant (216 mg) and Sino-implant (II) (150 mg) reported
somewhat similar rates of ectopic pregnancy as the Norplant
studies. Two studies of Jadelle included ectopic pregnancies,
Table 2
Proportion of pregnancies that were ectopic and ectopic pregnancy incidence by implant type and regimen among studies for which pregnancy location is
known.a
Progestin (dosage) No. of
studiesb
No. of
women
No. of studies
reporting any
ectopic pregnancies
% of pregnancies
that were ectopicc
Ectopic pregnancy
incidence per
1000 w-yc
Ever-marketed regimens
LNG
Norplant (6 silastic rods, 216 mg) [26–50] 25 61432 11 3.1–100 0.1–2.9
Jadelle (2 silastic rods, 150 mg) [46,47,78] 3 11391 2 20–33 0.4, d
Sino-implant (I) (6 silastic rods, 216 mg) [33,34,65,75,77] 5 22399 1 25 0.8
Sino-implant (II) (2 silastic rods, 150 mg) [34,65–67,69,70,75,77] 8 25425 3 8.3–20 0.2–0.8
ENG
Implanon/Nexplanon (single EVA rod, 68 mg) [68,76] 2 205654 1 2.3 d
Regimens studied but never marketed
LNG
Norplant II Covered Rods (2 silastic rods, 140 mg) [38,42,54,55,72] 5 3023 1 16.7 2.6
3–6 silastic capsules (30 mg each) [62,71] 2 657 1 3 8.3
3-keto-desogestrel
Single silastic implants (10, 20, 40 mcg/day) [64] 1 33 1 50 179.2
Single EVA implants (15 & 30 mcg/day) [64] 1 17 0 0 0
MA
4–6 silastic capsules (23–30 mg each) [56,61,62] 3 825 2 7.1–66.7 11.4–41.6
4 MA+1 or 2 LNG silastic capsules (20–30 mg each) [62] 1 244 1 8 3.7
Norgestrienone
1–6 silastic capsules (30–47 mg each) [57,63,71] 3 1131 2 6.2–11.1 4.5–51.8
Nestorone (NES)
3–5 silastic capsules or 1 silastic rod (35mg each) [59] 1 282 0 0 0
Nomegestrol acetate
Uniplant (1 silastic rod, 55 mg) [60] 1 1803 0 0 0
Norethindrone (NET)
3–5 silastic capsules or 1 silastic rod (20–40 mg each) [62,74] 2 199 0 0 0
a Site of implantation could not be determined for 3 studies.
b Some studies contained more than one progestin and/or regimen.
c Among studies that reported any ectopic pregnancies.
d Exposure time not reported.
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woman–years [47] and one at 84 months of use (incidence rate
could not be calculated) [78]. Two large randomized trials of
Sino-implant (II) did not report pregnancy location; however,
correspondence with authors indicated that all pregnancies were
intrauterine [75,77]. Postmarketing surveillance studies of
Sino-implant (II) in Kenya and Pakistan following 754
women reported a single ectopic pregnancy out of five
pregnancies occurring within the first year of use resulting in
an ectopic pregnancy rate of 0.8 per 1000 woman–years [69].
Pregnancy incidence in studies of the single-rod Implanon/
Nexplanon (containing 68mg of ENG) is even lower, withmost
studies reporting zero pregnancies. We found only two studies
of Implanon that reported any pregnancies, one with no ectopic
pregnancies [76] and one reporting five [68]. The latter study
was a review of surveillance data submitted to Australia's drug
regulatory agency, which included 218 unintended pregnancies
associated with Implanon use. Only 13 of those pregnancies
were believed to be true method failures, and it is not clear if the
five ectopic pregnancies were among that group. Exposure time
was also not captured in these data, so we could not calculate an
ectopic pregnancy incidence rate.3.1.3. Dose effect
Data on the effect of progestin dose on ectopic pregnancy risk
are limited; however, a couple of studies provide some evidence.
In a study in which women received 90- or 120-mg LNG
implants, an ectopic pregnancy incidence rate of 8.3 per 1000
women–years was observed for the two groups combined [62],
which is considerably higher than even the highest rates observed
in studies of Norplant or Jadelle, which contain 216 and 150 mg
of LNG, respectively. This may be because lower dose implants
have a lower daily release rate and thus are less effective in
preventing pregnancy, including ectopic pregnancy. An early
study comparing silastic and ethylene vinyl acetate (EVA) rods
containingENGwith release rates ranging from10 to 40mcg/day
resulted in three pregnancies, including one ectopic, among
womenusing a single silastic rod releasing 10or 20mcg/day [64].
3.2. Injectables
Two types of progestin-only injectables are included in this
review, depot-medroxyprogesterone acetate (DMPA) and
norethisterone enanthate (NET-EN), in several different dosages
(Table 3). Many injectable studies did not report pregnancy
location. After contacting study authors, we obtained
Table 3
Proportion of pregnancies that were ectopic and ectopic pregnancy incidence by injectable type and regimen among studies for which pregnancy location is
known.a
Progestin (dosage) No. of
studiesb
No. of
women
No. of studies
reporting any ectopic
pregnancies
% of pregnancies
that were ectopic
Ectopic pregnancy
incidence per
1000 w-y
Marketed regimens
DMPA
150 mg/3 months [82,87,92,95,96,98–100,102–106] 13 957215 1 1.0 c
104 mg/3 months (subcutaneous) [87] 1 266 0 0 0
NET-EN
200 mg/2 months [88,96,103] 3 1113 0 0 0
Regimens studied but never marketed
DMPA
100 mg im/3 months [104] 1 609 0 0 0
NET-EN
200 mg/70–84 days [85] 1 324 1 25.0 3.4
200 mg/3 months [102] 1 832 0 0 0
200 mg/2 months then 200 mg/3 months [100,103] 2 902 0 0 0
20 mg/month [93] 1 203 1 20.0 4.1
a Site of implantation could not be determined for 11 studies.
b Some studies contained more than one progestin and/or regimen.
c Exposure time not reported.
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and 12 of 18 DMPA studies.
Pregnancy rates in the 27 studies of injectable contraceptives
were low. Among 10 studies of DMPA for which the pregnancy
rate was reported or could be calculated, rates ranged from 0.1 to
1.7 per 100 woman–years [83,87,89,94,96–98,103–106].
Among studies of NET-EN, rates ranged from 0.3 to 6.6 per
100 woman–years [79,81,83,85,88,90,91,93,96,101–103].
Only three studies— two of NET-EN and one of DMPA—
reported any ectopic pregnancies. The two associated with
NET-EN use occurred in studies of nonmarketed regimens:
monthly administration of 20 mg [93] and 200 mg given every
74 or 80 days [85]. In the former study, the duration of use and
the time of the ectopic pregnancy were not reported. In the latter,
a total of four pregnancies were documented with one being
ectopic, and the ectopic pregnancy rate was 3.4 per 1000
woman–years. The ectopic pregnancy occurred approximately
40 days after the second injection in a woman with a history of
PID. Finally, four ectopic pregnancies were reported among
949,182 users of 150-mg im DMPA in a review of Planned
Parenthood Federation of America insurance data collected
between 1994 and 1998 [82]. The pregnancy data from this
review are incomplete, however, as site of implantation is only
documented for 37% of clients between 1997 and 1998
compared to almost 98% of clients between 1994 and 1995,
and the review does not report when the four ectopic pregnancies
occurred. We did not find any studies of the subcutaneous
formulation of DMPA reporting ectopic pregnancy.
4. Discussion
Contraceptive methods such as LNG or ENG-containing
implants are highly effective; in a Cochrane review, nopregnancies were reported in either the Implanon or Norplant
groups after 26,972 and 28,108 women–months of follow
up, respectively [107]. Among women not using contracep-
tion, 1–2% of pregnancies are ectopic. Studies of proges-
tin-only implants described in this review report higher
proportions of ectopic pregnancies in the event pregnancy
occurs; however, our review confirms that the absolute risk
of ectopic pregnancy is lower for women using these
methods compared with noncontraceptors. The large, multi-
country, postmarketing study of Norplant offers a good
example of this lowered risk. Investigators found an ectopic
pregnancy incidence rate of 0.3 per 1000 woman–years
among Norplant users compared with a rate of 2.66 among
women not using contraception. The ectopic pregnancy
incidence rate was even higher (9.24 per 1000 woman–
years) in a subgroup of women not using contraception who
were planning pregnancy [35]. In the present review, the
highest incidence of ectopic pregnancy reported among
marketed implants was 2.9 per 1000 woman–years, which is
close to that estimated for noncontracepting women (2.1 per
1000 woman–years [108]); most studies, however, reported
incidence below 1.0 per 1000 woman–years.
The only other progestin used in currently marketed
implants (Implanon/Nexplanon) is ENG. Only three studies
of implants containing this progestin report any pregnancies;
two of these studies were with the marketed product
Implanon including a review of postmarketing surveillance
data. While five of the 218 pregnancies reported in that
review were ectopic, because of data limitations, it is
unknown how many of them occurred among women who
had the device in situ [68]. The exceptionally low number of
reported failures in the literature makes Implanon/Nexplanon
the most effective hormonal contraceptive available.
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pregnancy is also extremely uncommon.
Compared with studies of implants, fewer injectable studies
report pregnancy location. This may be because very low
incidence of ectopic pregnancy among users of these methods
makes it unnecessary to clarify that all reported pregnancies are
intrauterine. While we cannot be certain that this is the case, the
fact that only six reports of ectopic pregnancy in three studies
exist in nearly 50 years of published literature on progestin
injectables supports such an assumption. Furthermore, each of
the three injectable studies that report ectopic pregnancy have
important limitations, including incomplete data [82], use of
very low dose of progestin [93] and a confounding risk factor for
ectopic pregnancy [85].
The clinical and epidemiological evidence indicate that
LNG-containing implants are more likely to result in an
ectopic pregnancy (or any pregnancy) than the ENG implant
or progestin-only injectables. The type and dose of progestin
resulting in various levels of ovarian suppression may play a
role. Implanon/Nexplanon, DMPA and NET-EN more
completely suppress ovulation, thus limiting the potential
for fertilization and implantation to occur in any location.
Studies of Implanon indicate that only 4% of Implanon users
ovulate by the end of the method's 3-year recommended
duration of use [109]. In contrast, among LNG implant users,
ovulation is suppressed only initially but then resumes in
many. By year 5 of use, more than half of Norplant users
ovulate regularly [110], and it is estimated that Jadelle use
suppresses ovulation in only 45–85% of menstrual cycles
[111]. Case studies (not included in this review) reporting
ectopic pregnancies in Implanon users who may have lower
plasma concentration of ENG due to drug interaction with
certain antiretrovirals or other drugs known to induce hepatic
enzymes [112–115] and, therefore, do not fully suppress
ovulation support this theory, as does the higher rate of ectopic
pregnancies among users of a lower-dose LNG implants [62].
While ovulation is more fully suppressed with use of
progestin injectables [116], contraceptive failure rates are higher
with DMPA and NET-EN than with implants. This could be
explained by the fact that, unlike implants, thesemethods depend
on women's ability to use them correctly, that is, come back for
reinjection on time. Nevertheless, in spite of the higher failure
rate, very few reported pregnancies among injectable users are
ectopic. Whymethod failure with use of injectables is less likely
to lead to ectopic pregnancy than LNG implants is unknown but
could be related to the particular effects the different progestins
have on target tissues, including the fallopian tubes.
Research primarily from the field of assisted reproduction
shows that sex steroids play a crucial role in regulating the
number and activity of ciliated cells in the fallopian tubes, the
primary mechanism of gamete and zygote transport [117].
Fallopian tubes containing an ectopic pregnancy show amarked
reduction in the number of ciliated cells compared with those
from women with an intrauterine pregnancy of the same
gestational age [118]. In vitro studies of ciliary function have
found that incubation with progesterone substantially reducesboth ciliogenesis [12] and ciliary beat frequency [119] in
fallopian tube cells in a dose-dependent fashion. It is likely that
synthetic progestins affect ciliary development and activity in a
similar way, although the effect of various progestins may differ
due their dose or structure/activity differences [120]. Current
and future contraceptive development efforts may consider
further exploration of the physiological mechanisms underlying
ectopic pregnancy risk with specific progestins.
The goal of the present analysis was to review all published
studies of implant and injectable progestin-only contraceptives in
order to describe ectopic pregnancy risk with use of these
methods. To obtain themost comprehensive information, we did
not restrict bywhether or not themethodwas evermarketed or by
study design. Formal meta-analysis was not appropriate due to
the heterogeneous study designs, outcome measures and study
populations in the reviewed studies. One limitation of our review
is that a number of studies, especially of injectables, did not
report pregnancy location, andwe cannot be sure that all reported
pregnancies were intrauterine. In addition, due to the breadth of
the review, we were unable to thoroughly assess the data quality
and risk of bias for each of the 81 studies included in the review.
Certainly, the ectopic pregnancy incidence rates reported in or
calculated from the studies in this review could be influenced by
many factors including length of study follow-up, ascertainment
of outcomes in individual studies and underlying and unmea-
sured confounding risk factors in the studied populations.
Women who choose to use implant or injectable contracep-
tion can be assured that use of these methods substantially
reduces their risk of pregnancy and, thus, ectopic pregnancy.
The substantial body of research reviewed here shows that
ectopic pregnancy risk among users of marketed implants and
injectables is considerably lower than that ofwomenwho are not
using contraception. While women who choose to use
LNG-containing implants, such as Jadelle or Sino-implant (II),
and their providers should be aware of potential signs of ectopic
pregnancy in the small chance that the method should fail, fear
of ectopic pregnancy should not be a deterrent for use or
provision of these methods.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.contraception.2015.08.016.
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